Response to: Cytokine pro­file of autol­o­gous con­di­tioned serum for treat­ment of osteoarthri­tis, in vitro eff ects on car­ti­lage metab­o­lism and intra-​articular lev­els after injec­tion – authors’ reply (pdf)

Mar­ijn Rut­gers, Daniël BF Saris, Wouter JA Dhert and Laura B Creemers

We thank Moser for his com­ments on the paper we pub­lished in a pre­vi­ous issue of Arthri­tis Research & Ther­apy. To dis­pel any con­cerns about the proper use of the prod­uct, the autol­o­gous con­di­tioned serum (ACS) in this study was pre­pared in a GMP (good man­u­fac­tur­ing prac­tice) facil­ity in strict accor­dance with the guide­lines sup­plied by the man­u­fac­turer (Orthogen, Düs­sel­dorf, Ger­many) and was injected six times at 3-​day inter­vals in accor­dance with the instruc­tions given.

Autol­o­gous con­di­tioned serum (Orthokine) is an effec­tive treat­ment for knee osteoarthritis(pdf)

A. W. A. Baltzer, C. Moser, S. A. Jansen and R. Krauspe

Osteoarthri­tis (OA) is preva­lent and dif­fi­cult to treat. Autol­o­gous con­di­tioned serum (ACS), mar­keted under the trade name Orthokine, is a novel, injectable antiarthritic derived from the patient’s own blood. The present study is the first time ACS has under­gone a con­trolled clin­i­cal trial.

Autol­o­gous con­di­tioned serum for the treat­ment of osteoarthri­tis and other pos­si­ble appli­ca­tions in mus­cu­loskele­tal dis­or­ders (pdf)

Anto­nio Frizziero, Erika Gian­notti, Francesco Oliva, Ste­fano Masiero, and Nicola Maffulli

The ther­a­peu­tic use of inter­leukin 1 (IL-​1) cytokine recep­tor antag­o­nists (IL-​1RA) has pro­moted the devel­op­ment of new bio­log­i­cal ther­a­pies for osteoarthri­tis (OA). Autol­o­gous con­di­tioned serum (ACS) is an alter­na­tive, safe and well-​tolerated treat­ment in OA. We per­formed a com­pre­hen­sive search of PubMed, Med­line, Cochrane, CINAHL, Embase, Sport­Dis­cus, Pedro and Google scholar data­bases using key­words such as ‘inter­leukin 1’, ‘osteoarthri­tis’ and ‘autol­o­gous con­di­tioned serum’.